Phase i study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

Leukemia

Volumn 25, Issue 5, 2011, Pages 872-874

  Moreau, P ^a   Cavallo, F ^b   Leleu, X ^c   Hulin, C ^d   Amiot, M ^e   Descamps, G ^e   Facon, T ^c   Boccadoro, M ^b   Mignard, D ^f   Harousseau, J L ^g  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b University Hospital   (Italy)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e Team 12   (France)

^f SANOFI   (France)

^g Rene Gauducheau Cancer Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AVE 1642; BORTEZOMIB; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR;

CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; KIDNEY VEIN THROMBOSIS; LETTER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; RECEPTOR, IGF TYPE 1; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 79955805214     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.4     Document Type: Letter

References (9)

1. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy Jr JD, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614-4626.
2. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of IGF-1 receptor tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221-230. (Pubitemid 38402114)
3. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005; 90: 706-707. (Pubitemid 40780900)
4. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366-369.
5. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083. (Pubitemid 37022647)
6. Girard P, Boissel JP. Clockwise hysteresis or proteresis. J Pharma-cokinet Biopharm 1989; 17: 401-402. (Pubitemid 19263326)
7. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89: 547-551. (Pubitemid 38691241)
8. Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Hercend T et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006; 177: 4218-4223. (Pubitemid 44359958)
9. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF et al. Insulin is a potent myeloma cell growth factor through insulin/ IGF-1 hybrid receptor activation. Leukemia 2010; 24: 1940-1950.